Compare · ARGX vs WENA
ARGX vs WENA
Side-by-side comparison of argenx SE (ARGX) and ANEW MEDICAL INC. (WENA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and WENA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX carries a market cap of $63.27B.
- ARGX has hit the wire 12 times in the past 4 weeks while WENA has been quiet.
- ARGX has more recent analyst coverage (25 ratings vs 0 for WENA).
- Company
- argenx SE
- ANEW MEDICAL INC.
- Price
- $1051.35+3.10%
- $0.75-2.99%
- Market cap
- $63.27B
- -
- 1M return
- +20.64%
- -
- 1Y return
- +48.46%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2022
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx upgraded by UBS with a new price target
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
Latest WENA
- SEC Form EFFECT filed by ANEW MEDICAL INC.
- ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
- SEC Form S-1 filed by ANEW MEDICAL INC.
- Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy
- ANEW MEDICAL INC. filed SEC Form 8-K: Leadership Update
- ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
- ANEW MEDICAL INC. filed SEC Form 8-K: Leadership Update
- ANEW MEDICAL INC. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke ("TTS")
- SEC Form 10-Q filed by ANEW MEDICAL INC.